StreetInsider.com News Articles

Cerenome to Hold CNSide® Business Update Call on September 30, 2026

Fri, 25 Sep 2026 07:30:00 -0400

HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced that management will host a conference call and webcast on Wednesday, September 30, 2026, at 8:30 a.m. Eastern Time to provide a business update on CNSide®, the Company's cerebrospinal fluid (CSF) diagnostic platform, offered through its wholly owned subsidiary, CNSide Diagnostics, LLC. The update will focus on recent commercial related developments including third-party billing, market access, expansion of the commercial team and broadening of the diagnostic testing

Cerenome to Hold CNSide® Business Update Call on September 30, 2026

Fri, 25 Sep 2026 07:30:00 -0400

Cerenome signs Blue Cross Blue Shield of Michigan coverage deal

Tue, 22 Sep 2026 07:31:25 -0400

Cerenome, Inc. (Nasdaq: CNSY) announced that its subsidiary, CNSide Diagnostics, LLC, signed an in-network provider agreement with Blue Cross Blue Shield of Michigan (BCBSM), effective September 1, 2026, to cover the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration assay.

BCBSM serves approximately 5 million commercial and Medicare Advantage members through Blue Cross Blue Shield of Michigan and Blue Care Network. Combined with previously announced agreements, CNSide's contracted reimbursement coverage now represents approximately 158 million commercial and Medicare Advantage covered lives.

"With BCBSM, CNSide now has contracted commercial and Medicare Advantage coverage representing approximately 158 million covered lives, further strengthening our national reimbursement platform

Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives

Tue, 22 Sep 2026 07:30:00 -0400

HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider agreement with Blue Cross Blue Shield of Michigan (“BCBSM”), effective September 1, 2026, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. BCBSM serves approximately 5 million commercial and Medicare Advantage members through Blue Cross Blue Shield of Michigan and Blue Care Network, one of the nation’s largest nonprofit Blue Cross Blue Shield organizations. Combined with previously announced

Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives

Tue, 22 Sep 2026 07:30:00 -0400

Form D CERENOME, INC.

Fri, 18 Sep 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260918/27081336.html

Cerenome names Samantha Fowlkes VP of commercial sales at CNSide

Wed, 16 Sep 2026 07:30:14 -0400

Cerenome, Inc. (Nasdaq: CNSY) has appointed Samantha Fowlkes as Vice President and Head of Commercial Sales for its CNSide Diagnostics division, according to a company statement.

Fowlkes most recently served as Vice President and U.S. Head of Client Clinical Operations at Caris Life Sciences. She previously held senior roles in strategic accounts and business development at Genoptix Medical Laboratory and Laboratory Corporation of America, spanning more than two decades in oncology diagnostics, precision medicine, and laboratory services.

Russell Bradley, President and General Manager of CNSide Diagnostics, said Fowlkes will lead the commercial expansion of the CNSide platform and strengthen relationships across the

Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division

Wed, 16 Sep 2026 07:30:00 -0400

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samantha Fowlkes as Vice President Head of Commercial Sales. Samantha will lead the commercial expansion of CNSide®, strengthening relationships across the oncology and pathology communities, and accelerate adoption of the CNSide platform by physicians and health systems.

“Samantha brings more than two decades of commercial leadership experience across oncology diagnostics, precision medicine and laboratory services, with a proven ability to build organizations and drive growth,” said Russell

Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division

Wed, 16 Sep 2026 07:30:00 -0400

Form 8-K CERENOME, INC. For: Sep 04

Thu, 10 Sep 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260910/27045496.html

Cerenome secures $20M financing deal with royalty-based repayments

Thu, 10 Sep 2026 07:15:44 -0400

Cerenome, Inc. (NASDAQ: CNSY), a central nervous system oncology company, announced it has entered into a senior secured financing agreement with 3i, LP for up to $20 million with royalty-based repayments.

Under the agreement, the company received initial funding at closing, with additional tranches available upon achieving certain milestones. The financing is intended to support the scale-up of Cerenome's laboratory-developed tests, including its CNSide® cerebrospinal fluid assay platform.

Andrew Sims, Cerenome's Chief Financial Officer, said the facility is "designed to be minimally dilutive to stockholders while supporting the next stage of commercial scale-up and development of CNSide, specifically growing sales and broadening

Cerenome secures $20M financing deal with royalty-based repayments

Thu, 10 Sep 2026 07:15:44 -0400

Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment

Thu, 10 Sep 2026 07:15:00 -0400

Capital will support continued CNSide® commercial scale-up and development

Initial tranche of funding provided at closing with future tranches linked to milestones

Forecasted cash runway now into 2028

HOUSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform of precision diagnostics, targeted therapeutics, and artificial intelligence, today announced that it has entered into a financing agreement with 3i, LP (“3i Fund”) for a senior secured facility of up to $20 million with royalty-based repayments. Under the agreement, the

Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment

Thu, 10 Sep 2026 07:15:00 -0400

Capital will support continued CNSide® commercial scale-up and development

Initial tranche of funding provided at closing with future tranches linked to milestones

Forecasted cash runway now into 2028

Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment

Thu, 10 Sep 2026 07:15:00 -0400

Capital will support continued CNSide® commercial scale-up and development

Initial tranche of funding provided at closing with future tranches linked to milestones

Forecasted cash runway now into 2028

Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment

Thu, 10 Sep 2026 07:15:00 -0400

Capital will support continued CNSide® commercial scale-up and development

Initial tranche of funding provided at closing with future tranches linked to milestones

Forecasted cash runway now into 2028

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Thu, 20 Aug 2026 07:30:00 -0400

Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal